Corium International Inc  

(Public, NASDAQ:CORI)   Watch this stock  
Find more results for CORI
+0.13 (3.36%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.74 - 4.02
52 week 3.14 - 16.29
Open 3.92
Vol / Avg. 45,707.00/73,896.00
Mkt cap 92.15M
P/E     -
Div/yield     -
EPS -1.64
Shares 22.29M
Beta     -
Inst. own 91%
Jul 27, 2016
Q3 2016 Corium International Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 13, 2016
Corium International Inc at Cantor Fitzgerald Healthcare Conference
Jun 8, 2016
Corium International Inc at Jefferies Healthcare Conference
May 10, 2016
Q2 2016 Corium International Inc Earnings Call
May 10, 2016
Q2 2016 Corium International Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -150.59% -69.52%
Operating margin -123.11% -51.38%
EBITD margin - -44.90%
Return on average assets -48.70% -34.18%
Return on average equity -189.01% -120.75%
Employees 247 -
CDP Score - -


235 Constitution Dr
MENLO PARK, CA 94025-1108
United States - Map
+1-650-2988012 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Corium International, Inc. is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules. Its Corplex and MicroCor platforms address the shortcomings of traditional transdermal drug delivery. Its marketed products include Clonidine TDS, which is a treatment for hypertension; Fentanyl TDS, which is a treatment for management of chronic pain, and Crest Whitestrips are a series of five products for oral care. Its Twirla is designed to deliver both hormones at levels comparable to low-dose oral contraceptives. Its MicroCor hPTH(1‑34) is a transdermal system designed to use its MicroCor technology to provide the delivery of parathyroid hormone.

Officers and directors

David L. Greenwood Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Peter D. Staple President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Robert S. Breuil Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Parminder Singh Ph.D. Chief Technology Officer, Vice President - Research & Development
Age: 52
Bio & Compensation  - Reuters
Joseph J. Sarret M.D. J.D. Chief Business Officer
Age: 48
Bio & Compensation  - Reuters
Robert W. Thomas Lead Independent Director
Age: 54
Bio & Compensation  - Reuters
Eric H. Bjerkholt Independent Director
Age: 56
Bio & Compensation  - Reuters
Bhaskar Chaudhuri Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Ronald W. Eastman Independent Director
Age: 63
Bio & Compensation  - Reuters
Phyllis I. Gardner M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters